


ASCO Annual Meeting, May 31 - June 4, 2024

Presentation schedule for Winship Cancer Institute of Emory University faculty and trainees

All times listed in Central Daylight Time



Friday, May 31, 2024

Time	Location	Type	Session	Presenter	Title
2:45 PM-5:45 PM	Arie Crown Theater	Oral Abstract Session	Lung Cancer—Non–Small Cell Metastatic	Ticiana Leal, MD (chair)	
2:45 PM – 2:51 PM	E451	Rapid Oral Abstract Session	Breast Cancer—Local/Regional/Adjuvant	Jane L. Meisel, MD	Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.

Saturday, June 1, 2024

Time	Location	Type	Session	Presenter	Title
8:28 AM – 8:40 AM	Hall D1	Clinical Science Symposium	Using “Artificial” Intelligence to Achieve “Real” Improvements in Cancer Care	Judy Gichoya, MD, MS	Discussion of Abstract(s) 100: Navigating Artificial Intelligence to Bring Better Care to All
9:00 AM-12:00 PM	Hall A	Poster Session	Developmental Therapeutics—Immunotherapy	Heather K. Lin, BS	Antagonizing vasoactive intestinal peptide (VIP) receptors with Muc16CD-directed armored CAR T cells for pancreatic cancer.
9:00 AM – 12:00 PM	Hall A	Poster Session	Developmental Therapeutics—Immunotherapy	Sunil S. Badve, MD	AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance.
1:30 PM-4:30 PM	Hall A	Poster Session	Pediatric Oncology	Brooke Cherven, PhD, RN	Factors associated with fertility status assessment among female survivors of childhood cancer.
3:00 PM – 3:12 PM	Hall B1	Oral Abstract Session	Breast Cancer—Metastatic	Kevin Kalinsky, MD, MS	Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Sunday, June 2, 2024

Time	Location	Type	Session	Presenter	Title
7:30 AM-9:30 AM	S103	Education Session	Training Program Directors’ Breakfast	Martha L. Arellano, MD (chair)	

8:00 AM-9:00 AM	Hall B1	Case-Based Panel	Advanced Prostate Cancer: A Case-Based Approach to Sequencing and Symptom Management	Kimberly A. Curseen, MD	Palliative Care Perspective
8:00 AM-11:00 AM	Hall D2	Oral Abstract Session	Gynecologic Cancer	Jane L. Meisel, MD (chair)	
8:36 AM – 8:48 AM	S100bc	Oral Abstract Session	Pediatric Oncology I	Jason R. Fangusaro, MD (discussant)	Discussion of Abstract(s) 10000-10002: Tyrosine Kinase Inhibitors in Central Nervous System Disease: Not a Blank Space
9:00 AM-12:00 PM	Hall A	Poster Session	Head and Neck Cancer	James Edward Bates, MD	Biomarker-driven radiation therapy dose reduction after transoral robotic surgery for the treatment of HPV-positive oropharyngeal cancer.
9:00 AM-12:00 PM	Hall A	Poster Session	Head and Neck Cancer	Reetoja Nag	Association of artificial intelligence–derived collagen disorder architecture (CoDA) features with survival outcome and objective response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma.
9:00 AM – 12:00 PM	Hall A	Poster Session	Genitourinary Cancer—Kidney and Bladder	Bassel Nazha, MD, MPH	Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study.
9:00 AM – 12:00 PM	Hall A	Poster Session	Genitourinary Cancer—Kidney and Bladder	Ahmet Yildirim, MD	Association of immune-related adverse events, inflammatory biomarkers, and clinical outcomes in patients treated with ICIs for advanced renal cell carcinoma.
9:00 AM – 12:00 PM	Hall A	Poster Session	Genitourinary Cancer—Kidney and Bladder	Ahmet Yildirim, MD	Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).
9:00 AM – 12:00 PM	Hall A	Poster Session	Genitourinary Cancer—Kidney and Bladder	Jacqueline Brown, MD	Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.
9:00 AM – 12:00 PM	Hall A	Poster Session	Breast Cancer—Metastatic	Manali A. Bhave, MD	Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course.
9:00 AM – 12:00 PM	Hall A	Poster Session	Breast Cancer—Metastatic	Manali A. Bhave, MD	Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
9:00 AM – 12:00 PM	Hall A	Poster Session	Breast Cancer—Metastatic	Kevin Kalinsky, MD, MS	pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).

9:00 AM – 12:00 PM	Hall A	Poster Session	Head and Neck Cancer	Nabil F. Saba, MD, FACP	STELLAR-305: A randomized phase 2/3 study of zanzalitinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
10:49 AM – 11:01 AM	Hall D1	Clinical Science Symposium	Next-Generation Antibody–Drug Conjugates: The Revolution Continues	Sagar Lonial, MD, FACP (discussant)	Discussion of Abstract(s) LBA105: Antibody, Linker, Drug: Teasing Apart What Matters
2:47 PM – 2:59 PM	Hall B1	Plenary Session	Plenary Session	Suresh S. Ramalingam, MD, FASCO, FACP	Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
4:30 PM-5:30 PM	S102	Case-Based Panel	Harness Artificial Intelligence to Enhance Patient–Physician Relationships	Judy Gichoya, MD, MS	Globalist Perspective
4:30 PM-6:00 PM	Arie Crown Theater	Clinical Science Symposium	The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer	Manali A. Bhave, MD (chair)	

Monday, June 3, 2024

Time	Location	Type	Session	Presenter	Title
9:00 AM – 12:00 PM	Hall A	Poster Session	Quality Care/Health Services Research	Elyse Xinyue Zhang, MPA	Association of enrollment in Medicare Advantage plans versus fee-for-service in patients with a late-stage diagnosis of gynecologic cancer.
9:00 AM-12:00 PM	Hall A	Poster Session	Gynecologic Cancer	Sarah Jeanne Wood, MD	Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer.
9:45 AM-11:00 AM	S504	Education Session	Pediatric Hodgkin Lymphoma Treatment: Paving the Way for a Standard of Care and Shared Decision-Making	Sharon M. Castellino, MD, MSc (chair)	Overview of Advances in Treatment of Hodgkin Lymphoma for Children, Adolescents, and Young Adults
11:30 AM-12:30 PM	S102	Case-Based Panel	Addressing Substance Use Disorders in the Context of Cancer: A Case-Based Discussion on Assessment and Management	Ali John Zarrabi, MD	Palliative Care Perspective
1:30 PM-4:30 PM	Hall A	Poster Session	Symptom Science and Palliative Care	Nicole C. Schmitt, MD	Randomized, placebo-controlled trial of atorvastatin to prevent hearing loss in patients with head and neck squamous cell carcinoma receiving cisplatin based chemoradiation (CRT).
1:30 PM-4:30 PM	Hall A	Poster Session	Medical Education and Professional Development	Keerthi Gogineni, MD, MSPH	Precision medicine preceptorship in breast and lung cancer for Latin American oncologists.
1:30 PM-4:30 PM	Hall A	Poster Session	Medical Education and Professional Development	Andrew Hearn, MD, MSCI	Demographic trends and outcome measures found in randomized controlled trials of wellness interventions among medical trainees: A systematic review.

1:30 PM – 4:30 PM	Hall A	Poster Session	Lung Cancer—Non-Small Cell Metastatic	Pushkar Mutha, MS	Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.
1:30 PM – 4:30 PM	Hall A	Poster Session	Lung Cancer—Non-Small Cell Metastatic	Mohammadhadi Khorrami, PhD	Association of combination tumor texture and vessel tortuosity with progression free survival across PD-L1 subgroups in durvalumab treated non-small cell lung cancer (NSCLC): Blinded validation results from CP1108.
1:30 PM – 4:30 PM	Hall A	Poster Session	Prevention, Risk Reduction, and Genetics	Donghai Liang, PhD	Metabolomics signatures of air pollution mixtures and lung cancer risk: A large-scale metabolome-wide association study in the Cancer Prevention Study cohorts.
1:30 PM – 4:30 PM	Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Ticiana Leal, MD	ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study.
4:24 PM – 4:36 PM	Hall B1	Oral Abstract Session	Breast Cancer—Local/Regional/Adjuvant	Kevin Kalinsky, MD, MS	Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).